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Abstract
Elevated serum concentrations of follicle-stimulating hormone (FSH) are associated with
diminished bone density in women, beginning years before menopause and the decline in
estradiol. We hypothesized that FSH promotes development of myeloid cells toward the bone-
resorbing osteoclast phenotype. This was tested by isolating peripheral blood mononuclear cells
from nine healthy adults, incubating them in the presence of FSH at three different concentrations
spanning the physiological range, and then measuring the expression of receptor activator for NF-
κB (RANK, a surface marker for osteoclasts) on CD14+ cells by flow cytometry. In the absence of
FSH, 3.3 ± 0.5% of the cells expressed high levels of the receptor (RANKhigh). Increasing
concentrations of FSH caused a biphasic dose-response, with a maximal (1.5-fold) increase in
RANKhigh cells achieved with 50 mIU/ml FSH (P = 0.02). Cytokines that influence development
of osteoclasts were also measured in culture supernatants: Macrophage colony stimulating factor
(M-CSF), osteoprotegerin (OPG) and tumor necrosis factor-α (TNFα) concentrations were not
significantly influenced by FSH, whereas RANK-ligand was undetectable. This study supports the
concept that the elevated circulating concentrations of FSH during perimenopause may contribute
to the increased rate of bone loss by promoting the development of osteoclast precursor cells.
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1.0 Introduction
The development of osteoporosis in older women is often associated conceptually with the
decline in circulating estradiol concentration that accompanies menopause. However, studies
involving pre- and perimenopausal women have shown that elevated serum concentrations
of follicle-stimulating hormone (FSH) correlate with diminished bone mineral density
(BMD) beginning years before menopause and the decline in estradiol [1,2]. In addition, a
meta-analysis of ten prospective studies found that the rate of spinal BMD loss during
perimenopause, when estradiol concentrations were still high, was greater than the rate of
loss in the years following menopause, when estradiol concentrations were much lower [3].
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Bone density depends on the balance between the activity of bone-forming osteoblasts and
bone-resorbing osteoclasts. We hypothesized that FSH promotes development of osteoclast
characteristics on circulating precursor cells, which comprise ~2% of the peripheral blood
CD14+ monocytes in humans [4,5]. These cells begin to express calcitonin and vitronectin
receptors, produce tartrate-resistant acid phosphatase and become capable of bone resorption
when cultured under appropriate in vitro conditions [4,5]. A critical stimulus for osteoclast
differentiation is transmitted via the receptor activator for NF-kB (RANK), a member of the
tumor necrosis factor (TNF) receptor superfamily [6]. This receptor has been identified on
circulating osteoclast precursor cells, making it a convenient surface marker for identifying
osteoclast precursors by flow cytometry [7].
Therefore, the primary aim of this investigation was to determine if FSH increased RANK
expression on CD14+ peripheral blood mononuclear cells isolated from healthy adults.
Induction of RANK on CD14+ precursor cells requires macrophage colony stimulating
factor (M-CSF) [8], therefore cell supernatants were assayed to determine if FSH influenced
the secretion of this critical cytokine. Further differentiation of precursors to mature
osteoclasts requires RANK ligand (RANKL) [6], which can be produced by activated T
cells [9]. The binding of RANKL to RANK can be inhibited if it is bound by the decoy
receptor osteoprotegerin (OPG) [6], which can be produced by B cells [10]. In addition,
evidence suggests that FSH can promote murine osteoclast precursor differentiation via
stimulation of TNFα [11]. Therefore the supernatants were also assayed to determine if FSH
altered the secretion of soluble forms of these factors.
2.0 Materials and Methods
2.1 Blood Collection
Nine healthy adults donated blood for these experiments. These donors included two men
(26 and 47 years of age), and seven women (22 to 57 years of age). All subjects provided
informed consent, and the protocol was approved by the Human Assurance Committee at
the Medical College of Georgia. The blood was drawn into three 10 ml heparinized
vacutainer tubes for immediate mononuclear cell isolation and one K2EDTA tube was
drawn for plasma, which was frozen at −70 °C for later analysis.
2.2 Cell Isolation and Culture
Mononuclear cells were isolated from the heparinized blood by density gradient
centrifugation using ficoll-hypaque (Sigma, St. Louis, MO), washed three times with sterile
saline (0.9% NaCl) and resuspended in phenol red-free RPMI-1640 medium supplemented
with 2 mM of L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 1% (by volume) 1
M Hepes Buffer (all from Sigma), and 1% heat-inactivated autologous plasma. Cells were
then distributed in sterile 12 × 75 mm polypropylene tubes (Fisher Scientific, Suwanee GA)
at a density of 2.5 × 106 cells/tube and incubated with 0, 10, 50, or 100 mIU/ml of highly
purified pharmaceutical grade human FSH (Bravelle, Ferring Pharmaceuticals, Suffern, NY)
for 18 hours at 37°C in a humidified 5% CO2 atmosphere. After incubation, cell
supernatants were collected, aliquotted and frozen at −70°C for later analyses. Receptor
expression on the cells was determined by flow cytometry.
2.3 Flow Cytometry
The mononuclear cells were washed, resuspended to 1 × 107 cells/ml, blocked with 1 mg/ml
human IgG (Sigma I8640), and then stained with phycoerythrin (PE)–conjugated anti-
RANK (9A725, Abcam, Cambridge, MA). A PE-conjugated murine IgG1 isotype control
(BD Biosciences, San Diego, CA) was used to test for nonspecific staining. Monocytes were
identified with an allophycocyanin (APC)-conjugated anti-human CD14 (M5E2, BD
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Biosciences) which was added to the cells at the same time as the anti-RANK. After
washing, the cells were fixed in 5% formalin/PBS, pH 7.3 and stored overnight at 4 °C. The
following day, flow cytometric analysis was performed once per sample using a Becton
Dickinson 2-laser, 4-detector FACSCalibur Flow Cytometer. Cell counts were restricted to
intact cells identified by a dual parameter plot of forward scatter versus side scatter. Multi-
color flow cytometry was performed with appropriate one-color controls for setting
compensation for spectral overlap.
2.4 Immunoassays
Concentrations of M-CSF, OPG, TNFα and RANKL were measured once in each
supernatant using a cytometric bead array (CBA, BD Biosciences, San Jose, CA)[12].
Separate bead populations were coated with murine capture antibodies raised against M-CSF
(#840689, R&D Systems, Minneapolis, MN), OPG (#840369, R&D Systems), TNF
(#51-9005468, BD Biosciences) and RANKL (# I1207, Peprotech, Rocky Hill, NJ). The
biotinylated detection antibodies were goat anti-M-CSF (#840690, R&D Systems), anti-
OPG (#840370, R&D Systems), anti-TNFα (#51-9004040, BD Biosciences) and rabbit anti-
RANKL (#I1307, Peprotech). Phycoerythrin-conjugated streptavidin was purchased from
Jackson Immunoresearch, West Grove, PA (#016-110-084). After incubation and washing,
the beads were resuspended and analyzed with a BD FACSArray flow cytometer. Analytes
were differentiated by bead fluorescence characteristics, and analyte concentration was
determined by the fluorescence intensity of the labeled detection antibody, which was
compared to standard curves generated with recombinant M-CSF (#840691, R&D Systems),
OPG (#840371, R&D Systems), TNFα (#51-9003509) and RANKL (#310-01, Peprotech).
2.5 Data Analysis and Statistics
Values reported are means ± standard errors. Differences between control and FSH
treatment conditions were assessed by repeated measures analysis of variance (ANOVA)
followed by Dunnett’s post hoc test for multiple comparisons to a control using Statview
software (SAS Institute, Cary NC). Statistical significance was accepted with a P value
<0.05.
3.0 Results
Illustrative flow cytometric dot plots and histograms of RANK expression on CD14+
monocytes are presented in Figure 1. Non-specific staining is illustrated in panels A and B,
wherein cells incubated without FSH and stained with isotype control antibody exhibited
relative fluorescence intensities (RFI) of <300. When stained with anti-RANK,10.0% of
control cells (no FSH) exhibited positive RANK expression (RFI >300, panels C and D).
Incubation with FSH (50 mIU/ml) resulted in 18.3% of cells expressing RANK, with much
of the increase occurring at very high RFI (>3 000): from 2.4% in the absence of FSH to
7.6% with 50 mIU/ml FSH.
Cumulative data for all subjects are presented in Figure 2. The total percentage of CD14+
cells exhibiting specific RANK expression was 8.5 ± 1.3% in control cultures, whereas
maximal expression, 10.4 ± 1.6%, was observed on cells incubated with 50 mIU/ml of FSH
(white bars, not statistically different from control). The expression of high levels of RANK
(>3 000 RFI) was also analyzed: In the absence of FSH, 3.3 ± 0.5% of the cells were
RANKhigh, whereas 4.9 ± 0.9% of the cells incubated with 50 mIU/ml were RANKhigh
(black bars in Figure 2A, P = 0.02), a 1.5-fold increase. Essentially all of the increase in
RANK+ cells was due to increased numbers of RANKhigh cells. No age or sex-dependent
influences on FSH-induced mononuclear cell RANK expression were observed in the
limited number of subjects tested.
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Basal RANK expression on CD14-negative cells was 3.5 ± 0.4%. FSH induced a small
increase in RANK expression, with maximal expression observed for cells incubated with
50 mIU/ml of FSH (4.4 ± 0.4%, P = not significant, white bars, Figure 2B). The mean
percentage of RANKhigh CD14-negative cells was less than 0.15% in any of the culture
conditions.
Mean M-CSF concentrations in control cultures were 500 ± 110 pg/ml, and incubation with
FSH had no influence on the M-CSF concentrations in the other cell culture supernatants
(black bars in Figure 3). The basal concentrations of OPG were low (6.8 ± 0.6 pg/ml), and
the concentrations did not change significantly in the supernatants of cells incubated with
FSH (dark gray bars in Figure 3). Basal TNFα concentrations were 470 ± 221 pg/ml, and
although the mean concentration was 47% higher in supernatants incubated with 100 mIU/
ml of FSH, this increase was not statistically significant (light gray bars in Figure 3).
RANKL was undetectable (< 2 pg/ml) in any of the supernatants.
4.0 Discussion
Previous studies have shown that FSH enhanced RANKL-stimulated osteoclastogenesis
from human peripheral blood mononuclear cells over 8 days of incubation [13]. The present
data indicate that one mechanism contributing to this effect is an increase in FSH-induced
RANK expression, which occurs within 18 hours.
FSH had no significant influence on RANK expression at a concentration of 10 mIU/ml,
which is in the range of the circulating follicular-phase FSH concentrations of women
during the majority of their reproductive years. However, FSH caused a significant increase
in RANK expression at 50 mIU/ml, concentrations typical during perimenopause that are
associated with increased bone loss [14]. At higher concentrations reached after menopause
(100 mIU/ml), FSH had less of an influence on RANK expression. These results are
consistent with clinical observations that the rate of spinal BMD loss is greater during
perimenopause than in the years following menopause [3].
FSH preferentially increased the numbers of CD14+ cells expressing high levels of RANK
(MFI >3 000). A previous study has shown that such CD14+ cells, with relatively high
expression of RANK, are more likely to differentiate into mature osteoclasts than are cells
expressing low or moderate levels of RANK [7]. This is consistent with the concept that
osteoclast precursors may be part of a distinct subpopulation of monocytes: It has also been
reported that monocytes capable of proliferation yield more osteoclasts than monocytes that
are incapable of proliferation [15].
In the present study, CD14-negative cells also expressed RANK. These results are consistent
with previous studies that have detected RANK on lymphocytes, primarily B cells and
natural killer cells [7]. The functional consequences of RANK expression on these cells are
not presently understood. RANK has also been identified on dendritic cells, and stimulation
by RANKL augments their ability to stimulate T cells [16].
No FSH-induced changes in soluble OPG or RANKL were observed in the present study.
However, it is not certain that the OPG and RANKL assays detected all possible forms of
these proteins since OPG monomers, dimers and OPG/RANKL complexes exist [17].
Furthermore, it is possible that FSH might influence RANKL signaling by affecting its
membrane-bound expression on CD14-negative mononuclear cells. RANKL-mediated
signaling is transmitted primarily in a juxtacrine manner via the membrane-bound form of
RANKL, rather than in a paracrine manner as a soluble mediator [6].
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Although a previous study found that recombinant FSH induced a significant increase in
TNFα secretion from murine bone marrow-derived macrophages [11], we found no
significant FSH-induced increase in TNFα secretion from human peripheral blood
mononuclear cells. In addition to the species and cell differences, the previous study used a
higher dose of FSH, 100 ng/ml, which would correspond to 1000 mIU/ml [18].
In summary, the present study indicates that FSH induces expression of RANK on CD14+
cells, indicating the acquisition of osteoclast precursor cell characteristics. These findings
may contribute to a mechanistic explanation for the increased rate of bone loss that occurs
during the perimenopausal period.
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Flow cytometry results from a single subject. A: Scatter plot for CD14+ gated cells (vertical
axis) versus PE- conjugated isotype control (horizontal axis); B: Histogram of the PE
fluorescence data of panel A; C: Scatter plot for CD14+ gated cells versus PE-conjugated
anti-RANK under control conditions without FSH; D: Histogram of the PE fluorescence
data of panel C; E and F: same as panels C and D, except cells were cultured with 50 mIU/
ml FSH. The vertical line indicates the demarcation between nonspecific and specific
staining (at an RFI of 300 for this subject).
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Mean RANK expression on CD14+ mononuclear cells (panel A) and CD14-negative cells
(panel B). The top of the white bars indicates the total percentage of RANK positive cells,
the black bars indicate the percentage of RANKhigh cells (RFI > 3000, extremely low in
panel B). *P = 0.02, compared to control condition (0 FSH). N=9.
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Concentrations of M-CSF (black bars, scale on left), OPG (dark gray bars, scale on right),
and TNFα (light gray bars, scale on left) in the supernatants of mononuclear cells cultured
with FSH.
Cannon et al. Page 9
Cytokine. Author manuscript; available in PMC 2012 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
